Axial Spondyloarthritis - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Axial Spondyloarthritis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Axial Spondyloarthritis - Pipeline Review, H1 2016', provides an overview of the Axial Spondyloarthritis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis
- The report reviews pipeline therapeutics for Axial Spondyloarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Axial Spondyloarthritis therapeutics and enlists all their major and minor projects
- The report assesses Axial Spondyloarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Axial Spondyloarthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Axial Spondyloarthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Axial Spondyloarthritis Overview 6
Therapeutics Development 7
Pipeline Products for Axial Spondyloarthritis - Overview 7
Axial Spondyloarthritis - Therapeutics under Development by Companies 8
Axial Spondyloarthritis - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Axial Spondyloarthritis - Products under Development by Companies 11
Axial Spondyloarthritis - Companies Involved in Therapeutics Development 12
AbbVie Inc. 12
Eli Lilly and Company 13
Johnson & Johnson 14
Novartis AG 15
Sandoz International GmbH 16
UCB S.A. 17
Xbrane Biopharma AB 18
Axial Spondyloarthritis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
adalimumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
certolizumab pegol - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
certolizumab pegol biosimilar - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
etanercept biosimilar - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
etanercept biosimilar - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ixekizumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
secukinumab - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ustekinumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Axial Spondyloarthritis - Recent Pipeline Updates 55
Axial Spondyloarthritis - Dormant Projects 88
Axial Spondyloarthritis - Product Development Milestones 89
Featured News & Press Releases 89
Jan 16, 2016: BENEPALI. the First Etanercept Biosimilar Referencing Enbrel, Approved in the European Union 89
Nov 06, 2015: UCB Presents Latest Research from Immunology Portfolio at American College of Rheumatology Annual Meeting 89
Sep 08, 2015: Merck and Samsung Bioepis Announce Approval of BRENZYS (Etanercept), a Biosimilar of Enbrel, in Korea 94
Nov 14, 2014: UCB Shows Strong Scientific Presence On Certolizumab pegol (CIMZIA) At Leading Rheumatology Meeting 94
Sep 20, 2013: UCB receives CHMP positive opinion for Cimzia in severe active axial spondyloarthritis 98
Jul 24, 2013: U.S. FDA Arthritis Advisory Committee Votes On Cimzia For Treatment of Adults with Active Axial Spondyloarthritis, Including Patients with Ankylosing Spondylitis 99
Jun 14, 2013: UCB's Certolizumab Pegol Rapidly Improves Pain, Fatigue And Physical Function In axSpA Patients In Phase III Study 100
Feb 20, 2013: UCB Announces Regulatory Filings For Cimzia To Treat Psoriatic Arthritis And Axial Spondyloarthritis 102
Nov 13, 2012: UCB Announces Presentation Of Phase III Trial Results Of Certolizumab Pegol In Axial Spondyloarthritis At ACR 2012 Annual Meeting 103
Nov 09, 2012: UCB To Present New Data On Certolizumab Pegol At ACR's 2012 Annual Scientific Meeting 104
Appendix 107
Methodology 107
Coverage 107
Secondary Research 107
Primary Research 107
Expert Panel Validation 107
Contact Us 107
Disclaimer 108

List of Tables

Number of Products under Development for Axial Spondyloarthritis, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Axial Spondyloarthritis - Pipeline by AbbVie Inc., H1 2016 12
Axial Spondyloarthritis - Pipeline by Eli Lilly and Company, H1 2016 13
Axial Spondyloarthritis - Pipeline by Johnson & Johnson, H1 2016 14
Axial Spondyloarthritis - Pipeline by Novartis AG, H1 2016 15
Axial Spondyloarthritis - Pipeline by Sandoz International GmbH, H1 2016 16
Axial Spondyloarthritis - Pipeline by UCB S.A., H1 2016 17
Axial Spondyloarthritis - Pipeline by Xbrane Biopharma AB, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Axial Spondyloarthritis Therapeutics - Recent Pipeline Updates, H1 2016 55
Axial Spondyloarthritis - Dormant Projects, H1 2016 88